The UK dominates the global market in legal cannabis production for medical and scientific purposes, accounting for 43% of such production worldwide by 2021. This growth was spurred by legalization in 2018, primarily driven by high-profile patient cases advocating for treatment. However, despite its production capabilities, domestic accessibility for patients remains alarmingly low, with the NHS issuing very few prescriptions due to strict guidelines. This situation presents a contradiction where the UK excels in a lucrative industry while its own citizens face hurdles in accessing these treatments.
The UK paradoxically leads in legal cannabis production for medical use but restricts access for its citizens, highlighting economic opportunity against prohibitionist policies.
Collection
[
|
...
]